Alirocumab
Benefit of alirocumab in moderate chronic kidney disease
Patients with chronic kidney disease (CKD) represent an important high cardiovascular risk group, especially in view of evidence that the prevalence of this condition is increasing rapidly world-wide. Statins with minimal renal excretion are the treatment of choice for management of the associated dyslipidaemia; however,…
read more »
Good news for PCSK9 inhibitors in diabetes patients
Findings reported for both evolocumab and alirocumab indicate promise for the PCSK9 inhibitors in patients with diabetes, with similar reductions in low-density lipoprotein (LDL) cholesterol as in nondiabetic patients. For evolocumab, there was also no difference in efficacy between 2-weekly and monthly regimens. A pooled…
read more »
ISA 2015: Alirocumab treatment well accepted by patients and clinicians
While injectable treatment is common among some specialities, this is not the case among clinicians managing patients with dyslipidaemia. PCSK9 monoclonal antibody, which is injected subcutaneously every 2 or 4 weeks, is undoubtedly effective in the management of high cardiovascular risk patients with elevated low-density…
read more »
ACC 2015 More safety data with PCSK9 inhibitors: patients with very low LDL-C
Accumulating data with both alirocumab and evolocumab have so far not indicated specific safety issues. In the latest reports at ACC 2015, there were no safety signals in more than 5,000 patients who achieved very low low-density lipoprotein (LDL) cholesterol levels (<25 or <15 mg/dL)…
read more »
ACC 2015 ODYSSEY CHOICE: Flexibility in alirocumab dosing
Results from the ODYSSEY CHOICE studies indicate flexibility in dosing with alirocumab, with 4-weekly regimens shown to be effective and well tolerated, according to Dr Michel Farnier, Point Medical, Dijon, France. Many patients at moderate to high cardiovascular (CV) risk and with poorly controlled hypercholesterolaemia…
read more »
